Intellipharmaceutics International Inc. Stock OTC Markets

IPCIQ

CA4581733090

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 22:46:37 03/03/2026 +04			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Valuation: Intellipharmaceutics International Inc.

Market Cap	1.28M 1.1M 1.02M 955K 1.79M 121M 1.81M 12.01M 4.68M 59.32M 4.81M 4.71M 206M	P/E Ratio 2021	-0.4x	P/E Ratio 2022	-0.91x
Enterprise Value	3.52M 3.04M 2.8M 2.63M 4.93M 333M 4.98M 33.04M 12.87M 163M 13.22M 12.94M 565M	EV / Sales 2021	-	EV / Sales 2022	74x
Free-Float	98.24%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Chart: Intellipharmaceutics International Inc.

Timeframe

Style

Dynamic Chart

Managers and Directors: Intellipharmaceutics International Inc.

Manager	Title	Age	Since
Amina Odidi DFI	Director of Finance/CFO	-	-
Fazayill Shaideen AUD	Comptroller/Controller/Auditor	-	01/04/2007
Christian Akyempon PRN	Corporate Officer/Principal	-	01/02/2014

Director	Title	Age	Since
Amina Odidi BRD	Director/Board Member	-	01/09/2004

More insiders

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Companyâ€™s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.

Employees

Sector

Pharmaceuticals

More about the company

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrows Top Investments!

SEIZE THE OFFER!

3 years	0		0.15
5 years	0		0.3
10 years	0		33.5

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTELLIPHARMACEUTICS INTERNATIONAL INC.	-.--%	-.--%	-	-	1.52M
ELI LILLY AND COMPANY	-0.61%	-2.32%	+37.00%	+147.28%	1,007B
JOHNSON & JOHNSON	-0.20%	+1.30%	+49.70%	+43.64%	567B
ABBVIE INC.	+0.40%	-0.27%	+16.43%	+63.71%	392B
ROCHE HOLDING AG	-0.80%	+1.05%	+20.91%	+18.37%	328B
NOVARTIS AG	-0.43%	+2.01%	+23.20%	+32.46%	277B
ASTRAZENECA PLC	+0.64%	-3.71%	+20.92%	+13.67%	275B
NOVO NORDISK A/S	-1.86%	+3.05%	-45.70%	-49.24%	196B
AMGEN INC.	-0.77%	+0.61%	+17.82%	+52.27%	189B
GILEAD SCIENCES, INC.	+2.36%	-0.68%	+15.68%	+61.05%	154B
Average	+0.05%	+0.33%	+17.33%	+42.58%	376.23B
Weighted average by Cap.	-0.14%	-0.03%	+25.91%	+66.88%

	2021	2022
Net sales	-	65.73K 56.64K 52.16K 48.97K 91.95K 6.21M 92.92K 616K 240K 3.04M 247K 241K 10.55M
Net income	-5.15M -4.43M -4.08M -3.83M -7.2M -486M -7.27M -48.25M -18.8M -238M -19.31M -18.9M -826M	-2.89M -2.49M -2.3M -2.16M -4.05M -273M -4.09M -27.12M -10.57M -134M -10.85M -10.62M -464M
Net Debt	1.15M 987K 909K 853K 1.6M 108M 1.62M 10.74M 4.18M 53.03M 4.3M 4.21M 184M	2.24M 1.93M 1.78M 1.67M 3.14M 212M 3.17M 21.03M 8.19M 104M 8.41M 8.24M 360M

Intellipharmaceutics International Inc. Stock OTC Markets

Stocks

IPCIQ

CA4581733090

Pharmaceuticals

Valuation: Intellipharmaceutics International Inc.

Chart: Intellipharmaceutics International Inc.

Course Extremes

Managers and Directors: Intellipharmaceutics International Inc.

Other Pharmaceuticals

Financials

Company Profile